GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Return-on-Tangible-Equity

Implantica AG (OSTO:IMP A SDB) Return-on-Tangible-Equity : 0.00% (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Implantica AG's annualized net income for the quarter that ended in . 20 was kr Mil. Implantica AG's average shareholder tangible equity for the quarter that ended in . 20 was kr Mil. Therefore, Implantica AG's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Implantica AG's Return-on-Tangible-Equity or its related term are showing as below:

OSTO:IMP A SDB's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.6
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Implantica AG Return-on-Tangible-Equity Historical Data

The historical data trend for Implantica AG's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Return-on-Tangible-Equity Chart

Implantica AG Annual Data
Trend
Return-on-Tangible-Equity

Implantica AG Semi-Annual Data
Return-on-Tangible-Equity

Competitive Comparison of Implantica AG's Return-on-Tangible-Equity

For the Medical Devices subindustry, Implantica AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Implantica AG's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Implantica AG's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Implantica AG's Return-on-Tangible-Equity falls into.


;
;

Implantica AG Return-on-Tangible-Equity Calculation

Implantica AG's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Implantica AG's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Implantica AG  (OSTO:IMP A SDB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Implantica AG Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Implantica AG's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines